Incentives for antibiotics: Recent papers, with an emphasis on Pull

Dear All: 

For your weekend reading list, I have some papers on the topic of (mostly pull) incentives for antibiotics.

First, I previously wrote about the survey from TATFAR (Transatlantic Task Force on Antimicrobial Resistance) of 6 possible pull models (higher reimbursement, diagnostic confirmation, market entry rewards both fully and partially delinked, tradable exclusivity vouchers, and an options market). The final paper is now out (Ardal et al., Clin Infect Dis, 15 Oct 2017) and is definitely worth reading. You’ll also want to (re)review their prior paper (Sciaretta et al., Clin Infect Dis, 2016) on push and pull incentives.

The short summary of these papers would be that (a) we need both Push and Pull incentives and (b) there is no perfect Pull incentive but the one that seems to provide the best balance of useful effects with minimal disruption is the idea of a market entry reward that uses relatively smaller rewards to top up market-based revenues. This is also sometimes called a partially delinked market entry reward model.

Consistent with this,a new paper from Towse et al. has recently appeared in Health Policy (disclaimer — I am a co-author on this paper). Entitled “Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation”, this paper compares a higher (premium) price Pull model with a partially delinked model. It concludes that:

  • A premium price model has uncertain impact and risks putting commercial return and appropriate stewardship in opposition.
  • An insurance model can achieve investment, reduce uncertainty for health systems, and achieve stewardship.

Third, don’t forget that DRIVE-AB is continuing to generate materials. Their July 2017 commentary to the G20 is consistent with all of the above and their final reports should start to appear soon.

Finally, IDSA’s Stakeholder Forum on Antimicrobial Resistance (http://s-far.org/) is a partnership of  more than 100 health organizations seeking to ensure that any U.S. government strategy to address antimicrobial resistance involves sustained and meaningful engagement with non-government experts and stakeholders throughout the policy development and implementation process. Their website provides links to a variety of key documents on AMR.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on whatsapp
Share on reddit

AMR Action Fund ($1b for P2-3): Video chat with new CEO! New committed funds!

Dear All, I’ve written before about the AMR Action Fund (9 Jul 2020 newsletter): In brief, it is ~$1b pledged by over 20 leading pharmaceutical companies to support the Phase 2-3 studies needed to bring 2-4 new antibiotics to approval by 2030 Stated differently, the AMR Action Fund provides Push incentives for Phase 2-3 to complement the Push Incentives

UK Antibiotic Subscription Pilot: Updates from a webinar

Dear All (and with thanks to Kevin Outterson for co-authoring), We’ve written and talked before from various perspectives about the groundbreaking UK NHS England-, NHS Improvement-, and NICE-sponsored antibiotic subscription pilot project: 10 Feb 2021: Fabulous 5-minute video explainer on the economics of antibiotics by Andrew Jack of Financial Times Superb discussions of Push/Pull, the role

Brilliant 5-minute video explainer of the AMR problem!

 Dear All, Andrew Jack of the Financial Times (FT) has produced a superb 5-minute video explainer of the AMR challenge! Featuring cameos from Kevin Outterson (CARB-X), Christine Ardal (Norwegian Institute of Public Health), and Manica Balasegaram (GARDP), the video deftly illustrates the economic challenge, the way that delinked Netflix-like models provide a solution, and the

Job with global impact: Director, CIDRAP Antimicrobial Stewardship Program

Dear All, Launched in 2016, the Antimicrobial Stewardship Program (ASP) at the Center for Infectious Disease Research and Policy (CIDRAP) of the University of Minnesota works to provide support globally to the the infectious disease community via such diverse activities as ASP-oriented podcasts, webinars, journal clubs, and other resources. CIDRAP itself is directed by the

Scroll to Top